Objective To observe the clinical efficacy of Shenmaisanjie capsules combined with

131

I treatment in differentiated thyroid carcinoma（DTC）and its effect on the prognosis of patients. Methods uated the efficacy of Shenmaisanjie capsules combined with

131

I therapy（observation group

41 cases）versus

131

I therapy alone（control group

47 cases）as the first treatment after surgery in patients with DTC. We assessed the changes in thyroglobulin（TG）

thyroglobulin antibody（TgAb）

C-reactive protein（CRP）

Karnofsky Performance Status（KPS）score

and thyroid color Doppler ultrasound findings after treatment. Results After 6 months

the levels of TG

TgAb

and CRP were significantly decreased in both groups（P

<

0.05）

with significantly greater reductions in the observation group than in the control group（P

<

0.05）. The observation group had a significantly higher KPS score than the control group（P

<

0.01）. There was a significant difference in the change in thyroid ultrasound results before and after treatment between the two groups（P

<

0.05）. The overall response rate in the observation group was significantly different from that in the control group（P

<

0.05）. Conclusion Shenmaisanjie capsules combined with

131

I therapy are superior to

131

I therapy alone in reducing inflammation

decreasing the levels of serum tumor markers

and improving the quality of life in patients who had thyroid cancer surgery.